Compare
Lisata Therapeutics, Inc. vs Serina Therapeutics, Inc. vs Regen BioPharma Inc vs BullFrog AI Holdings, Inc.
| Latest fiscal year | Lisata Therapeutics, Inc. LSTA | Serina Therapeutics, Inc. SER | Regen BioPharma Inc RGBP | BullFrog AI Holdings, Inc. BFRG |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | $170.0K | $130.0K | $236.6K | $116.7K |
| Revenue growth (YoY) | -83.0% | +132.1% | 0.0% | n/a |
| Gross margin | n/a | n/a | n/a | 18.8% |
| Operating margin | n/m | n/m | -143.1% | n/m |
| Net margin | n/m | n/m | -538.8% | n/m |
| Net income | -$16.59M | -$19.18M | -$1.27M | -$6.50M |
| EPS (Diluted) | -$1.91 | -$1.91 | -$0.05 | -$0.63 |
| Operating cash flow | -$15.95M | -$17.95M | -$383.6K | -$5.52M |
| Free cash flow | -$15.98M | -$18.01M | n/a | n/a |
| Cash & equivalents | $15.96M | $3.06M | $69.6K | $2.18M |
| Total assets | $17.74M | $6.95M | $274.6K | $2.81M |
| Total liabilities | $3.14M | $6.99M | $6.56M | $672.0K |
| Shareholders' equity | $14.86M | -$37.0K | -$6.28M | $2.14M |
| Return on year-end equity | -111.7% | n/a | n/a | -304.2% |
| Shares outstanding | 8.83M | 10.77M | 39.37M | 11.42M |
Revenue, most recent five fiscal years
| Fiscal year | Lisata Therapeutics, Inc. | Serina Therapeutics, Inc. | Regen BioPharma Inc | BullFrog AI Holdings, Inc. |
|---|---|---|---|---|
| Latest | $170.0K Ended 2025-12-31 | $130.0K Ended 2025-12-31 | $236.6K Ended 2025-09-30 | $116.7K Ended 2025-12-31 |
| 1 year earlier | $1.00M Ended 2024-12-31 | $56.0K Ended 2024-12-31 | $236.6K Ended 2024-09-30 | n/a |
| 2 years earlier | $0 Ended 2023-12-31 | $3.15M Ended 2023-12-31 | $236.6K Ended 2023-09-30 | $65.0K Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $34.0K Ended 2022-12-31 | n/a | $10.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $144.0K Ended 2021-12-31 | n/a | n/a |